Strong sales performance of Cresemba® (isavuconazole) in Asia Pacific and China drives the region's fourth milestone payment to Basilea this year

Allschwil, Switzerland, October 10, 2024

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with serious bacterial and fungal infections, today announced continued strong sales performance of the antifungal drug Cresemba^® (isavuconazole) from licensing partner Pfizer Inc. in Asia Pacific and China exceeded the sales threshold, triggering a USD 1.25 million milestone payment.

David Veitch, Chief Executive Officer of Basilea, said: “This is the fourth milestone payment for Asia Pacific and China this year and reflects Cresemba’s significant medical need and strong growth momentum in this region. We are pleased to see Cresemba expand its efforts continue to serve a medical need in patients suffering from life-threatening invasive fungal infections.”

The licensing agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries) and 16 countries in the Asia-Pacific region and China.

Cresemba is approved and marketed in more than 70 countries, including the United States, most EU member states and other countries within and outside Europe. According to the latest available market data, Cresemba’s total global sales in the twelve months between July 2023 and June 2024 were $505 million, up 20 percent year-on-year.¹

About isavuconazole (Cresemba^®)

Isavuconazole is an intravenous (IV) and oral azole antifungal drug, marketed under the trade name Cresemba^®. Basilea has entered into several licensing and distribution agreements for isavuconazole covering approximately 115 countries. In the 27 Member States of the European Union, as well as in Iceland, Liechtenstein and Norway, isavuconazole is approved for patients aged 1 year and older for the treatment of invasive aspergillosis and for the treatment of mucormycosis in patients receiving amphotericin B. inappropriate.² In China, the oral and intravenous formulations are approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the United States (US) and several other countries in Europe and beyond, including Japan and the UK³ It has orphan drug status in the US, Europe and Australia for its approved indications.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative medicines to meet the needs of patients with serious bacterial or fungal infections. We have successfully launched two hospital brands: Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. We also have preclinical and clinical anti-infective agents in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Then visit basilicum.com.

Disclaimer

This communication expressly or impliedly contains certain forward-looking statements, such as “believe,” “assume,” “expect,” “predict,” “project,” “may,” “could,” “could,” “will” or similar statements relating to Basilea Pharmaceutica Ltd, Allschwil and its activities, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors that may cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements anticipated by such statements are expressed or implied. forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and undertakes no obligation to update the forward-looking statements contained herein, whether as a result of new information, future events or otherwise.

For more information please contact:

You can download this press release from www.basilea.com.

References

IQVIA Analytics Link, June 2024. Market sales reported as moving annual total (MAT) in US dollars.
European Public Assessment Report (EPAR) Cresemba: https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba (accessed: October 9, 2024)
Registration status and approved indications may vary from country to country.